SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study

SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study

Abstract Background Sodium-glucose cotransporter 2 (SGLT2) inhibition is recognized for its evident renoprotective benefits in diabetic renal disease. Recent data suggest that SGLT2 inhibition also slows down kidney disease progression and reduces the risk of acute kidney injury, regardless of wheth...

Full description

Bibliographic Details
Main Authors: Zhijuan Wang, Jie Wei, Wenman Zhao, Rui Shi, Yuyu Zhu, Xunliang Li, Deguang Wang
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Lipids in Health and Disease
Subjects:
Sodium-glucose cotransporter 2 inhibition
High-density lipoprotein
Kidney function
Mendelian randomization
Online Access:https://doi.org/10.1186/s12944-024-02072-6

Internet

https://doi.org/10.1186/s12944-024-02072-6

Similar Items